12:00 AM
 | 
Apr 19, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trastuzumab-DM1 regulatory update

Roche said its Genentech Inc. unit plans to seek accelerated approval from FDA this year for trastuzumab-DM1 to treat metastatic HER2-positive breast...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >